Loading...
•
Jun 30, 2022
Protalix Q2 2022 Earnings Report
Protalix reported an increase in revenues from selling goods and from license and R&D services, and a decrease in cost of goods sold, research and development expenses, and selling, general and administrative expenses.
Key Takeaways
Protalix BioTherapeutics reported financial results for the second quarter ended June 30, 2022. The company recorded revenues from selling goods of $3.4 million and revenue from licenses and R&D services of $5.4 million. Net loss for the quarter was approximately $5.3 million, or $0.11 per share.
Revenues from selling goods increased by 6% to $3.4 million.
Revenue from licenses and R&D services increased by 69% to $5.4 million, primarily from the Chiesi Agreements.
Cost of goods sold decreased by 13% to $4.1 million due to decreased manufacturing costs.
Net loss decreased to $5.3 million, or $0.11 per share, compared to $11.2 million, or $0.25 per share for the same period in 2021.